Skyhawk's Oral Drug Halts Huntington's Decline, Eyes a Market in Waiting

BOSTON, MA – June 30, 2026 – In the high-stakes world of biotechnology, where hope is often measured in decimal points and years of waiting, Skyhawk Therapeutics just delivered a dataset that has the Huntington's disease community and investors sitting up and taking notice. The Boston-based company announced striking 12-month results from a Phase 1/2 trial of its oral drug, SKY-0515, suggesting it may not just slow, but potentially halt the progression of the devastating neurodegenerative disorder.

For the more than 40,000 symptomatic individuals in the U.S. living with Huntington's—a fatal genetic disease with no approved therapies to alter its relentless course—the news represents a significant beacon of hope. For Skyhawk, it’s a critical validation of its RNA-modulating technology platform and a major step toward disrupting a market defined by a profound unmet need. The company's stock will be one to watch as it translates this clinical promise into a commercial reality.

A Meaningful Halt in Clinical Decline

The data, presented at the European Academy of Neurology, goes beyond typical early-stage readouts. After twelve months, patients taking SKY-0515 showed remarkable stability and even improvement across a suite of metrics designed to measure the core components of the disease: functional capacity, motor control, and cognitive function. The results stand in stark contrast to the expected decline observed in natural history studies.

Perhaps the most impactful metric is the Total Functional Capacity (TFC) score, which assesses a person's ability to manage work, finances, and daily life. Patients on SKY-0515 showed a mean change of +0.07, effectively holding steady. This compares to a projected decline of -0.87 points over the same period for untreated patients, based on propensity score-weighted data from the large Enroll-HD observational study. In the context of a progressive disease, standing still is a profound victory.

Similarly, the Total Motor Score (TMS) improved by 2.00 points, defying an expected worsening of 2.21 points. Cognitive measures also showed stabilization or improvement. While these comparisons to historical data carry inherent limitations—clinical trial participants can differ from a general patient population—the consistency across all measures is compelling. One leading neurologist specializing in the disease noted that the sustained improvement in the composite score (cUHDRS) and the drug's effect on key biomarkers represent a potent combination for treating Huntington's.

Adding a powerful human dimension to the clinical data, Skyhawk also released survey results from clinicians and patients. After a year, a period during which Huntington's is expected to cause considerable worsening, not a single patient or doctor assessed the disease as having progressed. Instead, 65% of participants and 50% of clinicians reported seeing an improvement—a subjective but crucial indicator of a drug's real-world impact.

Innovation at the RNA Level

Behind these results is Skyhawk's proprietary SKYSTAR® platform, a sophisticated engine for discovering small molecule drugs that target RNA. Unlike traditional drugs that target proteins, Skyhawk’s approach works upstream, modifying the RNA messages that create those proteins. This allows the company to pursue what were once considered “undruggable” targets.

SKY-0515 exemplifies this strategy with a novel, two-pronged attack on Huntington's pathology. The drug is designed to reduce levels of two key culprits: the mutant huntingtin (mHTT) protein, the primary toxin that destroys nerve cells, and PMS1, a protein identified as a key driver of the disease's genetic instability and progression. The trial data confirms this mechanism is working in patients, showing dose-dependent reductions of mHTT protein in the blood by up to 69%, a figure one expert called one of the most dynamic he's seen from any therapeutic approach.

“This further confirms for us the exciting possibility that SKY-0515's compelling and consistent effect on the critical biomarkers of mHTT and PMS1 may offer Huntington's patients a type of therapy they have long deserved, in a convenient daily pill,” said Sergey Paushkin, Head of R&D at Skyhawk Therapeutics.

The success of this dual-action small molecule validates not just the drug itself, but the broader potential of the SKYSTAR platform. This was underscored last year when Skyhawk inked a major collaboration with Merck KGaA, potentially worth up to $2 billion, to develop similar therapies for other neurological diseases. Such deals provide non-dilutive capital and, more importantly, a powerful endorsement from a pharmaceutical giant, signaling confidence in the underlying technology.

The Strategic Path to a Multi-Billion Dollar Market

With promising Phase 1/2 data in hand, the key question for investors and patients is the path to market. Here, Skyhawk appears to be executing a deliberate and aggressive strategy. The company is already well into its pivotal Phase 2/3 FALCON-HD program, a global, placebo-controlled study that will provide the definitive evidence of efficacy and safety required for regulatory approval.

In a sign of both immense patient need and enthusiasm for the drug, the Australian and New Zealand arm of the study completed enrollment six months ahead of schedule. The global portion of the trial is actively enrolling across eight countries, aiming for a total of over 500 participants. This momentum is critical for shortening the timeline to a potential launch, which the company is already planning for as early as 2027.

Skyhawk's competitive advantage is clear: convenience. The current therapeutic landscape for Huntington's is barren of disease-modifying options. The pipeline includes promising but more invasive approaches like antisense oligonucleotides (ASOs), which require spinal injections, and gene therapies, which involve brain surgery. SKY-0515, as a simple daily pill, would offer a transformative improvement in quality of life and accessibility, likely making it a preferred first-line treatment if approved.

Recognizing this, Skyhawk has been making strategic moves. The company recently appointed Aaron Deves, an executive with experience launching neurological therapies, as Chief Commercial Officer to build out its market-access strategy. Furthermore, Australia's Therapeutic Goods Administration (TGA) has already granted SKY-0515 eligibility for a provisional approval pathway, potentially accelerating its entry into that market. These are the calculated chess moves of a company that believes it has a winner and is preparing to capture a market desperate for a breakthrough.